Success Stories: Massachusetts-based Indian Research Fellow Working in the Field of Epidemiology Secured EB1A Approval in Just 8 Days
Client’s Testimonial:
“Excellent service provided by Chen Immigration Lawyers. Must be recommended!!! I am very impressed with drafting recommendation letters and petition letters for my application. During my case preparation, my attorney was able to prepare all my documents within the committed time and I received all the responses within 24 hours from the attorney's office in a satisfactory manner. Thank you for helping me out with my I-140 application.”
On January 11th, 2022, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Fellow in the Field of Epidemiology (Approval Notice).
General Field: Epidemiology
Position at the Time of Case Filing: Research Fellow
Country of Origin: India
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: January 11th, 2022
Processing Time:8 days (Premium Processing Requested)
Case Summary:
A holder of NIW case approval back in 2020, our esteemed client in the field of epidemiology again contacted our law firm in January 2022 to help him in preparing a solid EB-1A (Alien of Extraordinary Ability) case on his behalf. He was well aware that we would go to lengths and do everything in our authority leading him to receive his EB1A approval successfully without any hurdles. Therefore, we proceeded to prepare a substantiated background check of his credentials and then started with the attorney-client retainer agreement.
Our custom-made petition packet included the crucial details required in acquiring a national interest waiver approval from USCIS as mentioned below:
- Firstly, we mentioned that he had received his M.B.B.S degree from India and M.P.H. degree in epidemiology at a very well-established University of Public Health, U.S. He is a highly qualified scientist with vast experience in the field, and this strong academic background laid the foundation for his current position as a research fellow at a reputed University-based hospital in the U.S. His ongoing research has also secured funding from the National Institutes of Health, and the Nestle Purina PetCare Global Resources, Inc.
- We noted his intended research work on understanding the risk factors underlying chronic diseases, the mechanisms underlying complex disorders, and the changes in molecular profiles in response to environmental exposure, voicing some of our nation’s and the world’s most pressing issues, including the need for improved diagnostic and treatment approaches to cancer and the improved prevention and treatment of mental, neuropsychiatric, and aging disorders.
- We were convinced by the quality of research he has already published (20 peer-reviewed articles (5 recently accepted for publication) and 1 book chapter) concluding that he is a vital researcher whose presence is a boon to the United States. His work has been cited 221 times by other experts in the field from at least 25 countries, an impressive number that underscores the extensive use of his work by fellow researchers. Not only did he publish his work and acquire a substantially high number of citations, but his vast skill set, clinical and research experience, and peer-review experience ensure he is among the very top of his peers. He has already completed 30 peer reviews at the time of EB-1A filing.
- Ultimately, this citation record, in concurrence with the above funding support, makes clear that our client’s research is marked by tremendous importance both to the nation and to his colleagues in the field.
- One of his six recommenders has the following to say about the client:
“[Client] is currently working on this critical problem, and he has already produced useful and impactful research, so I am confident that his work provides significant benefits to the United States as it seeks to deal with its rapidly aging population.”
Therefore, based on the aforementioned aspects, it is abundantly evident that our client is an influential member of his field who has conducted vital studies of direct benefit to healthcare U.S. and abroad. Thanks to premium processing, he received his EB1-A approval in just 8 days instead of waiting for months. We thus wish him all the success in his future endeavors.